ATF2 and neoplasm: Moreover, blocking the AP1 transcription complex (Jun, Fos, Maf and ATF2 protein subfamilies) leads to increased tumour sensitivity to endocrine therapy and delayed onset of resistance through the inhibition of both proliferative and survival signals [40].